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Oral Presentations S169CD127 expression on CD8 +T cells, consistent with their rapid
clonal expansion and differentiation. Multiplexed Luminex cytokine
analysis demonstrated high-level secretion of IL-18 and IL-1RA,
with no increased secretion of TNF, IL-1b or IL-17 despite severe
GvHD.
The four treated recipients demonstrated rapid donor engraft-
ment, but, unlike the controls, they were significantly protected
against clinical and immunologic GvHD: They displayed neither
the skin rash nor the profuse diarrhea noted in the control animals,
and flow cytometric analysis demonstrated control of T cell prolifer-
ation, maintenance of CD127 expression levels, and inhibition of
IL-18 and IL-1RA cytokine secretion.
Conclusions:We have established a robust model of MHC haploi-
dentical HSCT andGvHDusing anMHC-defined Rhesus macaque
colony.We find that unprotected primate GvHD is characterized by
rapid T cell proliferation, with concomitant loss of expression of
CD127 on CD8 +T cells. In addition, it is associated with high level
secretion of IL-18 and IL-1RA. Finally, we find that CD28/CD40-
directed costimulation blockade in combination with sirolimus can
effectively inhibit the clinical, cellular and serum hallmarks of
GvHD during primate haploidentical BMT. This approach thus
may deserve close scrutiny as a possible clinical strategy for GvHD
prevention.
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FEASIBILITY, SAFETY, EFFICACY AND IMMUNOLOGIC IMPACT OF DAILY
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RegulatoryTcells (Treg) are deficient in chronic graft-versus-host-
disease (cGVHD). Interleukin-2 (IL-2) is critical in Treg develop-
ment, expansion and activity. We hypothesized daily subcutaneous
(SC) ultra-low-dose IL-2 (8 weeks on, 4 weeks off) may expandTregs
in steroid-refractory cGVHD. We report phase-I IL-2 outcomes at
dose-levels:A) 0.310^6 IU/m2 andB)110^6 IU/m2.Dose-level-C
accrual is ongoing. Concurrent immunosuppression was allowed.
11 patients accrued; 7 and 4 at dose-levels-A and -B. Median age
was 44 years (30-57). Median time from HSCT and cGVHD was
1021 (420-4714) and 784 (117-2233) days. cGVHD sites were skin
(11pts),mouth (6pts), eyes (4 pts), liver (3 pts), lung (2 pts), esophagus
(1 pt). Patients had amedian of 3 (range, 1-3) concurrent immunosup-
pressives: steroids (11 pts), sirolimus (5 pts), MMF (5 pts), tacrolimus
(4 pts). Discontinued prior therapies were rituximab (6 pts), ECP
(4 pts), MMF (2 pts), sirolimus (2 pts), cyclosporine (1 pt), thalido-
mide (1 pt), denileukin-diftitox (1 pt), alemtuzumab (1 pt).
No dose-limiting toxicity (DLT) GVHD flare occurred. One pa-
tient (lvl-A) had CTC grade-4 hemolytic-uremic-syndrome after
Hemophilus-B bacteremia at 5 weeks of IL-2 (and prednisone, tacro-
limus, sirolimus), reported as a DLT. No other DLT occurred. An-
other patient (lvl-A) hadCTCgrade-4MRSApneumonia at 8 weeks,
unrelated to IL-2 (on prednisone, sirolimus, MMF; also had MRSA
pneumonia pre-IL-2). No other significant infection was docu-
mented. One patient (lvl-B) discontinued IL-2 at 4 days for CTC
grade-1 fatigue.
Of 9 evaluable patients, 5 had a partial response, 1 had a mixed re-
sponse, and 3 had stable disease. Responses were scored in skin and
liver (mouth, eye received topical therapy). 4 of 5 responders chose
extended IL-2 (range, 1.5-15 months) given clinical benefit. The
5th, with resolving liver cGVHD, had IL-2 withheld for MRSA
pneumonia. He died of progressive liver cGVHD off IL-2.
IL-2 induced a 3-5-fold increase in CD4 +CD25 + CD127- Tregs
(Table). At 1, 2, 4, 6 and 8 weeks, IL-2 increased Treg significantly
over baseline (median difference5 17, 36, 60, 62, 59; p5 0.03, 0.04,
0.06, 0.05, 0.03, respectively). Similar changes were not seen in NK,
NK-T, or conventional T-cells.
We identify feasibility, safety, and efficacy of IL-2 in refractory
cGVHD. Treg expansion was marked despite steroid and calci-
neurin-inhibitor use. Ultra-low-dose SC IL-2 is a promising strategy
for cGVHD therapy and in-vivo Treg expansion.Table. Summary Statistics for CD41CD251CD127- T-reg-
ulatory Cells: Absolute Counts
Week N Median (range) cells/mLTreg Pre 9 17.3 (1.7, 41.8)
1 8 26.3 (14.3, 97.5)
2 10 50.2 (5.7, 400.9)
4 7 87.5 (22.2, 227.0)
6 9 67.7 (7.4, 188.5)
8 7 52.5 (22.3, 235.6)12 7 32.2 (10.6, 47.3)On IL-2: Week 1-8; Off IL-2: Week 8-12.40
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Severe acute graft vs. host disease (GVHD) unresponsive to ste-
roid and other immunosuppressive therapy typically leads to poor
outcomes and high mortality. Case reports of human mesenchymal
stem cells (MSCs) used for the rescue of pediatric patients with
severe GVHD resistant to multiple second line agents has generated
interest in the therapy because of its potential efficacy and encourag-
ing safety profile. In this study we evaluate the risk/benefit profile of
MSCs (Prochymal) administered under an FDA Expanded Access
Program (Protocol 275) as a rescue agent for treatment resistant
GVHD in pediatric patients.
Methods: Children with Grade B-D aGVHD failing steroids and
other agents were eligible for enrollment. Patients were given 8 bi-
weekly infusions of 2  106 cells/kg for 4 weeks, with an additional
4 infusions weekly after day 28 in patients with a partial response, de-
fined as improvement in at least one organ without progression in
others.
Results: 59 patients (median age of 8 years, 61% male, 55% Cauca-
sian, 83% recipient of an unrelated graft, and 41% cord blood) were
treated. At baseline, the distribution of aGVHD grades B:C:D was 6
(10%): 20 (33%): 33 (57%). Themedian duration of aGVHDbefore
enrollment was 29 days, and patients failed an average of 3.2 lines of
treatment for GVHD. Organ involvement was 60% skin, 87% gas-
trointestinal, and 38% liver. At day 28, overall response (OR), defined
as organ improvement of at least one stage without worsening in any
other,was 64%;17%of patients had stable disease ormixed response;
and 19% experienced progression. By grade, 28 day ORwas 67% for
B, 75% for C, and 58% for D. Response by organ was recorded, with
47% of skin, 23% of GI, and 39% of liver GVHD completely
responding (stage 0) within the first 28 days of treatment.Overall sur-
vival through study duration (day 100) was 62%. Achieving an OR at
day 28 resulted in a significantly higher probability of survival when
compared to patients who progressed within the first 28 days (76%
vs 9%, p\0.05). Prochymal was generally well tolerated and there
was no evidence of ectopic tissue formation.
Conclusion: Treatment with Prochymal produced a 64% response
rate in patients with otherwise refractory severe GVHD patients by
day 28. Response to Prochymal correlated with improved overall
survival at 100 days. MSC therapy appears to have an excellent
risk/benefit profile and should be considered in pediatric patients
with GVHD non-responsive to steroids.41
PROCHYMAL IMPROVES RESPONSE RATES IN PATIENTSWITH STEROID-
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